Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

Highlight

• Durvalumab combined with gemcitabine and cisplatin significantly improves long-term overall survival in advanced biliary tract cancer (aBTC) compared to chemotherapy alone.
• At 48 months, the overall survival rate doubles with durvalumab plus chemotherapy (11.8% vs 4.3%).
• The safety profile is comparable between the durvalumab plus chemotherapy and chemotherapy alone groups, with manageable serious adverse events.
• This evidence supports durvalumab plus chemotherapy as the new first-line standard of care for aBTC.

Study Background and Disease Burden